================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 23, 2008
BARR PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
Delaware 1-9860 42-1612474
(State or other (Commission File (IRS employer
jurisdiction of incorporation) Number) Identification No.)
225 Summit Avenue, Montvale, NJ 07645
(Address of principal executive offices) (Zip code)
(201) 930-3300
(Registrant's telephone number including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On December 23, 2008, Teva Pharmaceutical Industries Limited ("Teva")
issued a press release announcing the completion of the merger of Barr
Pharmaceuticals, Inc. ("Barr") with a wholly-owned subsidiary of Teva. The
merger was approved by the shareholders of Barr at a special meeting held on
November 21, 2008. As a result of the merger, Barr became a privately-held
company, wholly-owned by Teva. Shares of Barr's common stock, which prior to the
merger traded on the New York Stock Exchange, are in the process of being
delisted from trading. The foregoing description of the press release does not
purport to be complete and is qualified in its entirety by reference to the
press release, which is attached as Exhibit 99.1 to this Current Report on Form
8-K and is incorporated herein reference.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
99.1 Press Release, dated December 23, 2008, issued by Teva
Pharmaceutical Industries Limited
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Barr Pharmaceuticals, Inc.
By: /s/ Deborah A. Griffin
------------------------------------
Name: Deborah A. Griffin
Title: Vice President and Treasurer
Date: December 23, 2008